Assetmark Inc. Buys 193,859 Shares of Pfizer Inc. $PFE

Assetmark Inc. grew its position in Pfizer Inc. (NYSE:PFE) by 8.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,428,467 shares of the biopharmaceutical company’s stock after purchasing an additional 193,859 shares during the quarter. Assetmark Inc.’s holdings in Pfizer were worth $61,877,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in PFE. Fiduciary Alliance LLC raised its position in Pfizer by 46.4% in the 3rd quarter. Fiduciary Alliance LLC now owns 145,263 shares of the biopharmaceutical company’s stock valued at $3,701,000 after purchasing an additional 46,043 shares in the last quarter. Y Intercept Hong Kong Ltd purchased a new position in shares of Pfizer in the 3rd quarter valued at $3,019,000. Vista Investment Partners LLC grew its position in shares of Pfizer by 236.1% in the 3rd quarter. Vista Investment Partners LLC now owns 69,613 shares of the biopharmaceutical company’s stock valued at $1,774,000 after buying an additional 48,900 shares during the last quarter. Money Concepts Capital Corp grew its holdings in shares of Pfizer by 29.9% during the third quarter. Money Concepts Capital Corp now owns 248,251 shares of the biopharmaceutical company’s stock worth $6,325,000 after purchasing an additional 57,188 shares during the last quarter. Finally, Generali Investments CEE investicni spolecnost a.s. increased its position in shares of Pfizer by 76.4% during the third quarter. Generali Investments CEE investicni spolecnost a.s. now owns 109,269 shares of the biopharmaceutical company’s stock worth $2,784,000 after purchasing an additional 47,319 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Price Performance

Shares of NYSE:PFE opened at $27.58 on Friday. The business’s fifty day moving average price is $25.81 and its two-hundred day moving average price is $25.19. Pfizer Inc. has a one year low of $20.92 and a one year high of $27.94. The stock has a market cap of $156.78 billion, a PE ratio of 20.28 and a beta of 0.47. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.28.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.25%. The company had revenue of $17.56 billion for the quarter, compared to analysts’ expectations of $16.93 billion. During the same period last year, the company earned $0.63 EPS. The firm’s revenue for the quarter was down 1.2% compared to the same quarter last year. On average, analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be issued a $0.43 dividend. The ex-dividend date is Friday, January 23rd. This represents a $1.72 annualized dividend and a yield of 6.2%. Pfizer’s payout ratio is 126.47%.

Wall Street Analysts Forecast Growth

PFE has been the subject of a number of research analyst reports. Zacks Research cut Pfizer from a “hold” rating to a “strong sell” rating in a research report on Monday, January 26th. Citigroup began coverage on shares of Pfizer in a report on Tuesday, December 2nd. They issued a “neutral” rating and a $26.00 target price for the company. UBS Group assumed coverage on Pfizer in a report on Tuesday, January 6th. They set a “neutral” rating and a $25.00 price target on the stock. The Goldman Sachs Group restated a “neutral” rating and issued a $26.00 price target on shares of Pfizer in a research report on Wednesday, November 5th. Finally, Morgan Stanley cut their price objective on shares of Pfizer from $32.00 to $28.00 and set an “equal weight” rating for the company in a research report on Friday, December 12th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, Pfizer presently has a consensus rating of “Hold” and an average target price of $28.00.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.